Inflammatory cytokine-induced insulin resistance pathways

Inflammatory cytokine-induced insulin resistance pathways are complex signaling networks where pro-inflammatory mediators disrupt normal metabolic processes. Key cytokines such as Tumor Necrosis Factor-alpha (TNF-alpha), Interleukin-6 (IL-6), and Interleukin-1 beta (IL-1b) are secreted by adipose tissue and immune cells in response to obesity and metabolic stress (Hotamisligil, 2006). These cytokines activate intracellular stress-sensitive kinases, most notably c-Jun N-terminal kinase (JNK) and Inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-beta), which catalyze the inhibitory serine phosphorylation of Insulin Receptor Substrate 1 (IRS-1) (Shoelson et al., 2006). This modification prevents the recruitment of Phosphoinositide 3-kinase (PI3K), thereby impairing downstream Akt activation and glucose transporter (GLUT4) translocation to the cell membrane. Additionally, these pathways can induce the expression of Suppressor of Cytokine Signaling (SOCS) proteins, which further attenuate insulin signaling by promoting the degradation of IRS proteins (Wellen & Hotamisligil, 2005). Chronic activation of these pathways is a primary driver of Type 2 diabetes mellitus and metabolic syndrome. Therapeutic strategies targeting these pathways include the use of monoclonal antibodies to neutralize cytokines or small molecules to inhibit the associated kinases, aiming to restore insulin sensitivity in patients with Type 2 diabetes and metabolic syndrome (Goldfine et al., 2010). Drugs like Infliximab and Salsalate have been investigated for their potential to improve glycemic control by targeting these inflammatory nodes. However, systemic modulation of these pathways carries risks of immunosuppression and increased susceptibility to infections. Despite these challenges, understanding these pathways remains crucial for developing targeted therapies for metabolic diseases.

Other names

Metabolic inflammationMetaflammationCytokine-mediated insulin resistance signaling

Neutralization of pro-inflammatory cytokines (e.g., TNF-alpha, IL-1beta) or inhibition of downstream stress-activated kinases (e.g., JNK, IKK-beta) to prevent the inhibitory serine phosphorylation of insulin receptor substrate (IRS) proteins, thereby restoring the PI3K/Akt signaling pathway and improving glucose homeostasis.